ImmunityBio Q1 net loss widens to $632.8 million; revenue more than doubled to $44.2 million

ImmunityBio Inc

ImmunityBio Inc

IBRX

0.00
  • ImmunityBio posted Q1 product revenue, net of USD 44.17 million, up 168% from a year earlier.
  • Net loss widened to USD 632.8 million; operating loss widened to USD 69.79 million.
  • Research and development expense climbed 41% to USD 67.99 million; selling, general and administrative costs rose 40% to USD 45.77 million.
  • Cash, cash equivalents, and marketable securities totaled USD 380.9 million at March 31, up from USD 242.8 million at Dec. 31.
  • QUILT-2.005 pivotal BCG-naïve CIS trial was fully enrolled with an sBLA submission on track for 2026; ANKTIVA unit sales volume rose 168% year over year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001326110-26-000059), on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.